The best anti-wrinkle serums of 2025, tested and reviewed
"If you're looking for a smoother appearance with fewer fine lines without using Botox, the most effective approach is to combine treatments," says Paula Brezavscek, the founder of Miami's Azala Skin Clinic. Along with daily use of high-SPF sun protection and complexion smoothers like micro-needling, Brezavscek recommends "a consistent, at-home, medical-grade skin care routine."
What that means in layman's terms: daily use of products with high concentrations of things like peptides and retinoids, ingredients that have been thoroughly researched, studied and proven to both build collagen and improve skin texture and, in the process, soften wrinkles.
"Peptides stimulate collagen production. As we age, collagen production declines, leading to wrinkles, sagging and thinner skin," explains Boston board-certified facial plastic surgeon Dr. Akshay Sanan. "Peptides can actually have a 'Botox-like' effect by relaxing facial muscles and reducing the depth of wrinkles caused by repetitive movements."
In addition to peptides, studies show that, over time and with consistent use, retinol — one of many vitamin A compounds known as retinoids — effectively reduces the appearance of fine and even deeper lines. "Retinol and retinoids are highly effective at reducing the appearance of wrinkles and improving overall skin texture," says Sanan. "They work by targeting the root cause of wrinkles — collagen breakdown. By increasing collagen, retinoids thicken the dermis, reducing the depth of fine lines and wrinkles."
I'm 51, and I spent the past 18 months testing anti-wrinkle serums on my own increasingly lined face. Read on for the ones I found most effective — and those we definitely would not recommend.
The best anti-wrinkle serum of 2025
Other top anti-wrinkle serums we recommend for 2025
How we tested anti-wrinkle serums
Other anti-wrinkle serums we tested that didn't make the cut
What to look for in an anti-wrinkle serum
Anti-wrinkle serum FAQ
Meet the experts
I spent the past 18 months testing more than a dozen anti-wrinkle serums, applying each one at least once daily for 4 to 8 weeks. I rated them on efficacy (did my fine lines soften?), absorbency, ease of use, texture, versatility (is the product safe for many skin types?), ingredient quality, ingredient potency and value.
I tested Esteé Lauder's famous Night Repair Serum and found that it didn't absorb well into my skin and instead pilled in a gross way, knocking it out of consideration. Though it's often included in other best lists, Glow Recipe's Peptide Serum was inferior in all ways to the two I chose to include above — it has a sticky, tacky texture and didn't seem to do much for my skin. And, while I regularly recommend RoC retinol products, during this testing period, I found the formulas more irritating and harsh but with similar benefits to (the much less expensive) Differin gel.
Look for high potency of key ingredients — actives like peptides should be listed in the first five ingredients. For safety reasons, only purchase skin care from trusted retailers and reputable brands.
Most dermatologists recommend proactive, preventative use of anti-aging serums starting in your late 20s and early 30s, as this is when collagen production starts to slow down. But it's equally never too late to begin a quality skin care regimen — consistent application of targeted, high-quality products, plus religious use of daily sunscreen will go a long way to improve your skin at any age. "Wearing a broad spectrum sunscreen of SPF 30 or higher daily is a non-negotiable for me," says Dr. Melanie Palm, a board-certified dermatologist and cosmetic surgeon at San Diego's Art of Skin MD. "If you aren't protecting your skin from UV damage, all your best efforts — skin care, diet, lasers, injectables — are going down the drain."
This depends on the number of steps of your personal skin-care routine, but, as a rule, serums should always come after cleansing but before moisturizing. You want the active ingredients to really sink into your face, so the cleaner your skin, the better. Dermatologists also recommend using these products at night to give them even more time to absorb while you sleep.
Many anti-aging serums are potent and the ingredients can be irritating and harsh — and not safe for everybody. If your skin is sensitive or ultra-dry, or if you are pregnant or breastfeeding, check with your doctor before adding these to your skin-care regimen.
Dr. Akshay Sanan, MD, Boston board-certified facial plastic surgeon
Paula Brezavscek, the founder of Miami's Azala Skin Clinic.
Kimberly Austin, an aesthetician at the Los Angeles 7QSpa
Dr. Melanie Palm, MD, a board-certified dermatologist and cosmetic surgeon at San Diego's Art of Skin MD

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 days ago
- Yahoo
‘On the Rise' with Vanessa Freeman: How Botox helps with maintaining hairstyles
NEW YORK (PIX11) — Botox has been around for decades, and while it's primarily used to get rid of unwanted facial lines and wrinkles, it's finding its way into the hair care industry by helping people maintain their mane. Upkeeping the perimeter of your hair, or 'edges' as they are by some, has become a billion-dollar industry, as cited in a Business Insider Article. More Local News Girl Boss, Wendy Pittman is a busy grandmother and business owner. She loves working out, but wants to stay fit without the frizz. 'My hair has a curly pattern to it, so I work out, even if I pin it up, and tie it under a silk scarf when that comes off, all of this here that is left out of the sew-in is like poof!' Pittman said. More: Latest News from Around the Tri-State Dr. Jeanine Downie, a Montclair dermatologist has been experimenting with using botox to keep hair sweat-free for years. 'I did it on myself and I saw that it really worked and so I started offering it to my patients and it's been about three years and my patients love it,' Dr. Downie said. Wendy is among a growing number of Dr. Downie's patients, going from the salon chair to her doctor's chair, to maintain their hair styles. 'A lot of my patients question whether it's actually going to hurt the hairline. The answer is absolutely not. This boosts their image, it makes them feel better, it makes them stand taller, and makes them feel more elegant and more in charge of their lives.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
6 days ago
- Yahoo
ABBV or BMY: Which Biopharma Giant Has Better Prospects for Now?
AbbVie, Inc. ABBV and Bristol Myers Squibb BMY are leading drugmakers with broad and diverse portfolios and a global footprint. AbbVie is a global, diversified biopharmaceutical company with a dominant position across key therapeutic areas, including immunology, neuroscience, oncology, aesthetics and eye care. On the other hand, Bristol Myers is focused on discovering, developing and delivering transformational drugs for oncology, hematology, immunology, cardiovascular, neuroscience and other diseases. Both of these biopharma/biotech giants have strong footholds in their targeted businesses, delivering consistent returns to shareholders. In such a scenario, choosing one stock over the other can be tricky. Let us delve into their fundamentals, potential growth prospects, challenges and valuation levels to make a prudent choice. AbbVie's flagship drug Humira has lost patent protection both in the United States and Europe. Biosimilar competition significantly eroded the drug's sales in 2024, and the decline is expected to be sharper in 2025. Nonetheless, the acquisition of Botox maker Allergan for $63 billion in May 2020 has bolstered the product portfolio and lowered its dependence on Humira. ABBV's immunology drugs Skyrizi and Rinvoq have put up a stellar performance and positioned it well for long-term growth. These drugs are witnessing strong uptake across their approved indications, especially in the popular inflammatory bowel disease space, which includes two conditions, ulcerative colitis and Crohn's disease. Strong sales of these drugs have enabled AbbVie to offset the decline in sales of the blockbuster drug Humira. AbbVie has also built a strong oncology franchise with drugs like Imbruvica and Venclexta. Label expansion over the past couple of years have significantly expanded the eligible patient population for Venclexta. This, in turn, is boosting sales of the drug. In October 2024, AbbVie gained approval for Vyalev, a transformative therapy for treating advanced Parkinson's disease. Approval of new drugs further expands ABBV's portfolio. AbbVie has several promising R&D programs with the potential to drive long-term growth. This includes next-generation approaches in immunology, a focus on bispecifics, ADCs, as well as innovative therapies for neuropsychiatric and neurodegenerative disorders. The company has also been active on the M&A front. It acquired ImmunoGen, which added antibody-drug conjugate, Elahere and neuroscience drugmaker Cerevel Therapeutics in 2024. As of March 31, 2025, AbbVie had $64.5 billion in long-term debt and $5.4 billion in short-term debt/obligations on its balance sheet. Cash and cash equivalents totaled approximately $5.2 billion. However, increasing competitive pressure on Imbruvica and slowing sales of its aesthetics franchise are major headwinds, along with declining Humira sales. BMY's Growth Portfolio, comprising drugs like Reblozyl, Breyanzi, Camzyos and Opdualag, has stabilized its revenue base amid generic competition for its legacy drugs. Thalassemia drug Reblozyl has put up a stellar performance since its approval, posting strong growth in the United States and international markets. The drug is expected to contribute significantly in the coming decade. Sales of its oncology drug, Opdualag, have also been robust, fueling the top line. Strong growth in the U.S. market and encouraging uptake in newly launched markets have boosted sales. Strong momentum in Camzyos should further drive growth. Opdivo continues to maintain momentum on consistent label expansions. The FDA approval of Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use should help extend the impact of its immuno-oncology franchise to patients into the next decade. Other drugs like Zeposia and Krazati should also contribute to top-line growth. The company has made strategic acquisitions to broaden its portfolio and drive top-line growth. The recent FDA approval for xanomeline and trospium chloride (formerly KarXT), an oral medication for the treatment of schizophrenia in adults, was approved under the brand name Cobenfy. The approval of Cobenfy for schizophrenia broadens BMY's portfolio and validates the acquisition of Karuna Therapeutics. While the newer drugs boost sales, generic competition for legacy drugs, which account for the majority of total revenues, is a significant headwind and will affect top-line growth in the near term. Legacy Portfolio revenues declined 20% in the first quarter due to continued generic impact on Revlimid, Pomalyst, Sprycel and Abraxane, as well as the U.S. Medicare Part D redesign effect. Nonetheless, BMY is looking to boost its bottom line through cost-cutting initiatives. While BMY's strategy of acquiring companies with promising drugs and candidates is encouraging, this has resulted in substantial debt to finance these acquisitions. As of March 31, 2025, the company had cash and equivalents of $12.1 billion and a long-term debt of $46.1 billion. The Zacks Consensus Estimate for ABBV's 2025 sales implies a year-over-year increase of 6.6%, and that for earnings per share (EPS) suggests an improvement of 20.65%. However, EPS estimates for 2025 have moved south in the past 60 days. Image Source: Zacks Investment Research The Zacks Consensus Estimate for BMY's 2025 sales implies a year-over-year decrease of 4.13%, while that for EPS suggests an increase of 487.83%. The extraordinary EPS growth rate is attributed to an extremely low EPS figure in 2024 due to acquisition expenses. EPS estimates for both 2025 and 2026 have moved south in the past 60 days. Image Source: Zacks Investment Research From a price-performance perspective, ABBV has fetched better returns than BMY so far this year. Shares of ABBV have gained 11.8%, while those of BMY have lost 11.2%. The large-cap pharma industry has gained 1.6% in the said period. Image Source: Zacks Investment Research From a valuation standpoint, we use the P/E ratio of the large-cap pharma industry to compare these companies. Going by the same, ABBV is slightly more expensive than BMY. ABBV's shares currently trade at 14.76X forward earnings, higher than 7.60X for BMY. The large-cap pharma industry currently trades at 15.16X forward earnings. Image Source: Zacks Investment Research Both ABBV and BMY have an attractive dividend yield. This is a strong positive for investors. However, BMY's dividend yield of 5.20% is higher than ABBV's 3.4%. Large pharma/biotech companies are generally considered safe havens for investors interested in this sector. However, with both ABBV and BMY stocks currently carrying a Zacks Rank #3 (Hold), choosing one over the other is a complex task. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. ABBV has a strong and diverse portfolio. Immunology drugs Skyrizi and Rinvoq maintain momentum for the company. However, declining Humira sales, increasing competitive pressure on Imbruvica and slowing sales of its aesthetics franchise are major headwinds for the company. BMY's efforts to revive the top line in the face of generic challenges for key drugs are commendable. Approval of new drugs and label expansion of key drugs should generate incremental revenues for the company. However, we believe there is still time before the efforts reap a harvest for the company. The outlook for 2025 indicates challenges as of now. While both companies deal with patent cliffs, we believe ABBV is a better pick at present, primarily due to the diversity and strength of its portfolio. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 days ago
- Yahoo
Botulinum Toxins Market worth $15.7 billion by 2030 with 11.7% CAGR
DELRAY BEACH, Fla., July 11, 2025 /PRNewswire/ -- The global Botulinum Toxins Market, valued at US$8.1 billion in 2024 stood at US$8.9 billion in 2025 and is projected to advance at a resilient CAGR of 11.7% from 2025 to 2030, culminating in a forecasted valuation of US$15.7 billion by the end of the period. The rising societal emphasis on maintaining a youthful appearance, especially within urban environments and professional contexts, is driving an increasing number of individuals to seek out cosmetic procedures, with botulinum toxins (commonly known as Botox) being among the most popular options. This trend is not restricted to developed nations; in emerging economies, the combination of rising disposable incomes and heightened exposure to Western urban lifestyles is unveiling new demographic groups that are increasingly demanding these cosmetic treatments. Factors contributing to this shift include the influence of social media, where images of youthful faces are amplified, and the cultural valorization of beauty, which places pressure on individuals to look young to compete effectively in professional arenas. Moreover, advancements in the safety and accessibility of botulinum toxin procedures, along with growing awareness of the minimally invasive nature of these treatments, are expected to further fuel market growth. As a result, the botulinum toxins market is projected to experience substantial expansion throughout the forecast period, driven by these changing societal norms and economic factors. Download PDF Brochure: Browse in-depth TOC on "Botulinum Toxins Market" 400 - Tables50 - Figures320 - Pages By product, Botox has a wide range of approved uses and a well-documented safety and efficacy profile. Its consistent diffusion properties lead to desirable results, particularly in cosmetic applications. Additionally, Botox has proven effective in various therapeutic settings, including chronic migraines, dystonia, and spasticity. The use of Botox spans multiple medical fields, including neurology, dermatology, urology, ophthalmology, and rehabilitation medicine, contributing to its growing demand. Furthermore, Botox is supported by comprehensive training modules and patient support programs. These factors have helped Botox secure a significant share of the botulinum toxins market in 2024. By type, the type A botulinum toxins segment holds the largest market due to its proven clinical efficacy and well-established safety profile, supported by a long history of regulatory approvals. It is preferred over type B botulinum toxins because its effects are more noticeable at lower doses, and it has fewer adverse effects. Type A was the first serotype widely favored, backed by substantial evidence regarding its effectiveness and safety for both therapeutic and aesthetic purposes. Furthermore, type A is approved for a broader range of indications worldwide, including chronic migraine, spasticity, and the reduction of facial wrinkles, which has significantly contributed to its popularity. Additionally, type A botulinum toxins typically have a longer duration of effect, lasting between three and six months. This results in fewer treatment sessions and greater convenience for patients. By application, the botulinum toxins market is divided into two main applications: cosmetic and therapeutic applications. Among these, cosmetic applications are expected to dominate the market, particularly in the area of wrinkle removal. Since 2024, wrinkle removal has become a highly recognized and sought-after use of botulinum toxins, especially among adults looking for non-surgical anti-aging solutions. Clinics report a high volume of patients primarily seeking treatment for forehead lines, crow's feet, and glabellar (frown) lines. This popularity can be attributed to the visible results and relatively quick outcomes associated with the procedure, requiring fewer repeat treatments, which appeals to a wide range of demographics. Additionally, the procedure duration is short, and patients see quick results, making it a preferred choice in non-surgical treatments. By end user, the botulinum toxins market is segmented by end user into dermatology clinics & hospitals, beauty centers, medical spas, other end users, and home care settings. In 2024, dermatology clinics & hospitals held the largest market share. The growing adoption of automated systems in dermatology clinics can be attributed to several key factors that significantly enhance their operational efficiency. As these facilities increasingly integrate advanced technologies, the demand for automation has surged. This trend is not only driven by the desire for improved accuracy in diagnostics and treatments but also by the need for streamlined workflows that can reduce patient wait times and optimize resource allocation. Furthermore, the growing awareness among healthcare professionals about the advantages of automated systems plays a crucial role in their adoption. Clinics are recognizing that automated technologies, such as artificial intelligence-powered diagnostic tools and robotic-assisted treatment devices, can lead to better patient outcomes and greater satisfaction. As dermatology practices continue to evolve, the combination of technological innovation and enhanced patient care will likely contribute to a significant increase in market share for this segment. By geography, the region is distinguished by significant technological innovation and a well-established healthcare infrastructure. It is home to key players involved in the manufacturing and distribution of botulinum toxins. Over the past five years, there have been major developments, expansions, and deals in this area. Favorable macroeconomic indicators, such as supportive funding for startups, manufacturing-friendly regulatory frameworks, and strong healthcare infrastructure, indirectly promote market growth. Request Sample Pages : The key players profiled in the botulinum toxins market are AbbVie, Inc. (US), Ipsen Biopharmaceuticals Inc. (France), Revance Therapeutics, Inc. (US), Evolus, Inc. (US), Hugel, Inc. (South Korea), Medytox, Inc. (South Korea), Daewoong Pharmaceutical Co., Ltd. (South Korea), Merz Pharmaceuticals GmbH (Germany), Supernus Pharmaceuticals, Inc. (US), and Galderma (Switzerland). AbbVie Inc. (US): AbbVie Inc. is a global biopharmaceutical company with six product segments: Immunology, Hematologic Oncology, Aesthetics, Neuroscience, Eye Care, and Other Key Products. Its Aesthetics division provides a wide range of solutions, such as Botox Cosmetic, Juvéderm Collection, and other aesthetic products, including facial injectables, regenerative medicine, body contouring, and skincare items. AbbVie is a leading company in the global medical aesthetics market. Its major strength lies in a strong emphasis on research and innovation, which enables the discovery and development of innovative pharmaceutical products. AbbVie's diverse global presence also contributes to maintaining a robust product pipeline. AbbVie has strategically positioned itself as one of the most well-known biopharmaceutical companies globally, especially in the aesthetics market. The company continues to expand its portfolio with FDA approvals and the launch of new product lines. These include Botox Cosmetic for facial treatments, the Juvéderm Collection for restoring lost volume, and SKINVIVE to smoothen the skin on the cheeks. All of these products are experiencing increased aesthetic demand, which gives AbbVie a competitive advantage in the skincare market. Additionally, AbbVie has further innovated in body contouring with CoolSculpting and has diversified its medical solutions in Neuroscience, Oncology, and Eye Care. Ipsen Biopharmaceuticals Inc. (France) Ipsen Biopharmaceuticals Inc. is a leading specialty biopharmaceutical company, renowned for its botulinum toxin product, Dysport, which is well-established in the therapeutic market. Dysport has received approvals in over 80 countries and is commonly prescribed for various neuromuscular disorders, including upper and lower limb spasticity, cervical dystonia, and pediatric cerebral palsy. While Ipsen has formed strategic partnerships to enhance its presence in the aesthetic segment, its primary strength remains in the medical field. The company is actively engaged in clinical development for new therapeutic indications and has secured a significant share of the global market for therapeutic botulinum toxins, particularly in Europe, Latin America, and parts of Asia. Ipsen's botulinum toxins business offers a stable and growing revenue stream, driven by ongoing geographic expansion and the pursuit of unmet medical needs. Galderma (Switzerland) Galderma excels through its innovative product portfolio and strong regulatory achievements, establishing the company as a leader in dermatology and injectable aesthetics. With robust manufacturing capabilities and a new facility in Singapore, Galderma is well-positioned for sustainable growth. The company maintains a strategic focus on innovation and global expansion, reinforced by strategic alliances that strengthen its dominance in dermatology. Galderma sets itself apart with advanced technologies, including Relfydess, a type A botulinum toxin. Its extensive range of products in injectable aesthetics, dermo-cosmetics, and therapeutic dermatology provides effective solutions for various skin issues. For more information, Inquire Now! Related Reports: Monoclonal Antibody Therapeutics Market GLP-1 Analogues Market Drug Discovery Services Market Pharmaceutical Drug Delivery Market Pharmaceutical Contract Manufacturing Market Get access to the latest updates on Botulinum Toxins Companies and Botulinum Toxins Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data